Anti-GM attitude 'paradoxical': Amman
07 July, 2003 by Graeme O'NeillDr Klaus Amman is puzzled by the furore over pollen drift from genetically modified crops - "Pollen did not learn to fly with transgenes," he said.
Freebasing flies point to new treatments for addiction
07 July, 2003 by Melissa TrudingerThe administration of freebase cocaine to fruit flies has uncovered novel pathways central to the development of addiction and may eventually lead to the development of drugs to cure or prevent it.
Poverty, not GM, threatens biodiversity
07 July, 2003 by Graeme O'NeillAfrica's leading molecular geneticist told a forum on genetically modified organisms that poverty, not GM crops, posed the biggest threat to biodiversity around the world.
Pentrix goes to Phase II
04 July, 2003 by Jeremy TorrAustralian Cancer Technology (AustCancer)’s anti-cancer vaccine Pentrix is about to enter critical Phase II trials for its efficacy as a disease delay compound against cancer.
EQiTX appoints new R&D man
04 July, 2003 by Jeremy TorrPerth oil exploration company-turned-biotech EQiTX has signaled a new level of intent for its ambitions with the appointment to its board of ex-Pfizer R&D director Dr Kevin Fahey.
Biotech IPO breaks the drought
04 July, 2003 by Jeremy TorrSelect Vaccines, the first biotech floating an IPO in 2003, has shown the way for investors with a 150 per cent oversubscription from the money market.
Artificial heart trials commenced
03 July, 2003 by Melissa TrudingerThe much-anticipated clinical trial of Ventracor's artificial heart has commenced, with the implantation of the device in the first patient at the Alfred Hospital in Melbourne on the weekend.
Big pharma looking for early-stage partners: GSK exec
03 July, 2003 by Melissa TrudingerPartnering with big pharma was increasingly occurring at the early stage of drug development, including pre-clinical and Phase I, a Melbourne conference was told today.
Biotech to inject life into sugar industry
03 July, 2003 by Pete YoungA $54 million Cooperative Research Centre using biotech to inject fresh life into the economics of the sugar industry is due to open for business next month.
Bresagen sues IMVS for $7million
03 July, 2003 by Jeremy TorrFollowing aborted preclinical trials in the UK, Bresagen is to institute proceedings against pathology agency IMVS (Institute of Medical and Veterinary Science) and others involved in initial trials on potential anti-cancer compound E21R.
Amrad forecasts profit, acquisitions
02 July, 2003 by Jeremy TorrAmrad’s bulging coffers and a good prognosis have helped it forecast an overall profit for the year to June 2003, according to latest figures from the company.
Virax brings in Clearview
02 July, 2003 by Melissa TrudingerMelbourne company Virax (ASX: VHL) introduced shareholders to its strategy for partnering in a video conference with US bio-partnering specialists Clearview Projects yesterday, in a move designed to raise shareholder awareness of the partnering process and its importance to biotechnology companies.
Starpharma gets gel trial nod
02 July, 2003 by Jeremy TorrDendrimer nanotechnology company Starpharma has submitted an Investigational New Drug (IND) application to the FDA for Phase I clinical trials on its SPL7013 vaginal microbicide gel.
InterSuisse backs tanning drug
01 July, 2003 by Jeremy TorrMelbourne-based biotech EpiTan has sealed a deal with stockbroking firm Intersuisse Corporate Pty Ltd to underwrite $2,500,000 worth of shares in the company.
Iliad scores drug discovery funding
01 July, 2003 by Jeremy TorrANU spin off Iliad Chemicals has gained $2million worth of research funding from life sciences VC Start-up Australia Ventures Pty. The money will be ploughed into investigation of complex molecule technology as an anti-cancer agent.
